(All dollar amounts are in U.S. dollars (“$”) unless otherwise specified) Q4 2017 Highlights Positive Free Cash Flow of $0.75 million for Q4 2017 with $8.04 million in cash exiting 2017Adjusted EBITDA of $2.28 million for Q4 2017; six consecutive months of positive Adjusted EBIT...Read More
- Baseline demographics of TransCon Growth Hormone phase 3 heiGHt Trial presented - - Multiple ascending dose cohorts from TransCon PTH phase 1 clinical trial reinforced infusion-like profile over 24 hours - COPENHAGEN, Denmark, March 19, 2018 (GLOBE NEWSWIRE) -- Ascendis P...Read More
COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will hold a conference call and...Read More
TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) announced today that it plans to release its fourth quarter and year end 2017 results after the market close on Wednesday, March 21,...Read More
COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,947,368 American Depositary Shares (“ADSs”), each of which represents one ord...Read More
COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares (“ADSs”), each of...Read More
COPENHAGEN, Denmark, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upc...Read More
TORONTO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) today issues a correction to the drilling results reported within the January 18, 2018 press release, with the updated informatio...Read More
NI 43-101 Technical Report targeting significant increase in mine life expected Q2 2018 TORONTO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) announces the results from an additio...Read More
Positive Free Cash Flow for Q4 2017 with US$8.0 million in cash exiting 2017Record tonnes milled in December; production increased by 81% since January 2017Guidance for 2018: Free Cash Flow of US$14-$20 million; EBITDA of US$32-$40 million TORONTO, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Ascendant...Read More
COPENHAGEN, Denmark, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today provided an update on its rare disease endocrinology pipelin...Read More
COPENHAGEN, Denmark, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced it has reached its target enrollment in the phase...Read More
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upcoming i...Read More
Adjusted EBITDA1 of $1.6 million in NovemberRecord tonnes hoisted in November and Q4 production gains expected to drive robust operating and financial results in 2018Milled production tonnes up 67% year to date TORONTO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND)...Read More
TORONTO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) reports that operations at its El Mochito mine in Honduras are continuing normally despite uncertainty following the General Elections h...Read More
COPENHAGEN, Denmark, Nov.21, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upcoming inves...Read More
- Phase 3 Program for TransCon Growth Hormone Advances and TransCon PTH Enters the Clinic - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN, Denmark, Nov.16, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCo...Read More
Adjusted EBITDA1 of $1.3 million in OctoberMilled production increased to 2,184 tpd; up 67% year to dateNew fleet arrivals to drive production growth in Q4 2017 and 2018 TORONTO, Nov.14, 2017(GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Comp...Read More
Highlights Include: Net income of $821,000 and $0.01/shareThird consecutive month of positive adjusted EBITDA1; $2.4 million total for Q3 201775% increase in revenue versus Q2 2017Operating cash flow before changes in working capital of $2.3 million; Free cash flow expected before the end of Q4M...Read More
TORONTO, Nov.02, 2017(GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company") announced today that it plans to release its third quarter 2017 results after the market close on Monday, November 13, 2017. Management will host a conference call...Read More